News in brief

Sabinsa gets patent on LactoSpore’s mood benefits

By Hank Schultz contact

- Last updated on GMT

Sabinsa photo
Sabinsa photo

Related tags: Depression, Cognitive health, Gut health, Probiotics

Sabinsa has announced a new patent, this one for the effect of its Lactospore probiotic in the suppression depression symptoms in consumers suffering from gut health issues.

The patent, issued under the number US10166261, is for a method of managing dementia and dementia-related sleep disorders presented as symptoms of major depressive disorder (MDD) in humans associated with Irritable Bowel Syndrome (IBS) by administering Bacillus coagulans​ MTCC 5856 (LactoSpore) at a dose of 2 billion colony forming units per day.

The patent also mentions the ingredient’s ability to reduce serum myeloperoxidase, which is a biomarker of MDD.

The patent application was supported by a 2018 clinical study, published in the peer-reviewed journal Food & Nutrition Research ​titled ​Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, doubleblind, placebo controlled, multi-centre, pilot clinical study.” ​The study showed LactoSpore was reported to reduce depression symptoms in adults with IBS. 

“It is gratifying that the US patent office recognized the strain specific action of Sabinsa’s MTCC 5856 in allowing the claims,”​ said Shaheen Majeed, President Worldwide, Sabinsa. “We anticipate being granted patents on the discovery in additional countries in the near future.”

Related news

Show more

Related products

show more

DHA ORIGINS™: The sustainable potential of algae.

DHA ORIGINS™: The sustainable potential of algae.

Fermentalg | 22-Jun-2020 | Technical / White Paper

Consumers find out about nutritional quality by closely scrutinizing the labeling and list of ingredients (clean label). They are interested in the provenance...

Related suppliers

Follow us

Products

View more

Webinars